Rockefeller Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$126K Buy
5,331
+13
+0.2% +$324 ﹤0.01% 2928
2026
Q2
$129K Hold
5,318
– – ﹤0.01% 2837
2026
Q1
$82.4K Buy
5,318
+4,250
+398% +$70.5K ﹤0.01% 2986
2025
Q4
$20.3K Buy
+1,068
New +$15.3K ﹤0.01% 3517
2023
Q1
– Sell
-385
Closed -$4K – 3236
2022
Q4
$4K Buy
385
+328
+575% +$3.96K ﹤0.01% 3385
2022
Q3
$0 Hold
57
– – ﹤0.01% 4223
2022
Q2
$0 Buy
+57
New +$646 ﹤0.01% 4304

Other funds holding NRIX

Rockefeller Capital Management's NRIX Position: Q3 2026 in Review

Rockefeller Capital Management increased its Nurix Therapeutics (NRIX) stake by 0.24% in Q3 2026, buying an estimated $324 and bringing the position to 5,331 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #2928.

Rockefeller Capital Management first reported a position in NRIX in Q2 2022 and has held it in 7 quarters since. The position peaked at $129K in Q2 2026. 233 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Rockefeller Capital Management held 5,331 shares of Nurix Therapeutics worth $126K as of Q3 2026.
  • Rockefeller Capital Management bought 13 Nurix Therapeutics shares in Q3 2026, an estimated $324.
  • Nurix Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #2928 holding.
  • Rockefeller Capital Management first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • Rockefeller Capital Management's Nurix Therapeutics position peaked at $129K in Q2 2026.
  • 233 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.